CAIM
TARS icon

Catherine Avery Investment Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Catherine Avery Investment Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$594 – 165
2025
Q3 		$594 Sell
10
-10
-50% -$492 ﹤0.01% 156
2025
Q2 		$810 Buy
20
+7
+54% +$315 ﹤0.01% 154
2025
Q1 		$668 Sell
13
-7
-35% -$346 ﹤0.01% 149
2024
Q4 		$1.11K Buy
+20
New +$908 ﹤0.01% 148

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Catherine Avery Investment Management's TARS Position: Q4 2025 in Review

Catherine Avery Investment Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 10 shares — an estimated $594 sold.

Catherine Avery Investment Management first reported a position in TARS in Q4 2024 and held it in 4 quarters. The position peaked at $1.11K in Q4 2024. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Catherine Avery Investment Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Catherine Avery Investment Management sold 10 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $594.
  • Catherine Avery Investment Management first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Catherine Avery Investment Management's Tarsus Pharmaceuticals position peaked at $1.11K in Q4 2024.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Catherine Avery Investment Management's 13F filing for Q4 2025, filed 5 Jan 2026.